Skip to main content
SpringerLink
Log in

Is Antibiotic Resistance in Cutaneous Propionibacteria Clinically Relevant?

Implications of Resistance for Acne Patients and Prescribers

  • Current Opinion
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

It is well recognized that some patients with acne do not respond adequately to antibiotic therapy. It is important to distinguish antibiotic recalcitrant acne which we would suggest represents acne that shows a diminished response to treatment irrespective of the cause as opposed to ‘antibiotic-resistant acne’ which is acne that is less responsive to treatment as a direct consequence of skin colonization with resistant propionibacteria. Here we show that antibiotic-resistant acne is not just a theoretical possibility but a real phenomenon that could have important consequences for patients and prescribers. The relationship between skin colonization by antibiotic-resistant propionibacteria and treatment outcomes is a complex one that is explained at the follicular level by physiological differences affecting local drug concentrations. A systematic review of the literature on antibiotic-resistant propionibacteria revealed methodological shortcomings in studies of their prevalence and a paucity of evidence on their clinical significance. Despite the elucidation of resistance mechanisms in cutaneous propionibacteria, our continuing inability to distinguish between strains of Propionibacterium acnes means that we still do not fully understand how resistance spreads, although person-to-person transfer is most likely. Finally, we present a decision tree for acne management in an era of prudent antimicrobial prescribing that provides an alternative to existing treatment algorithms by placing topical retinoids and not antibiotics at the cornerstone of acne management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV
Table V
Table VI
Fig. 1
Table VII

Similar content being viewed by others

Notes

  1. Although reductions in propionibacterial numbers at the skin surface are not large, topical clindamycin appears to be capable of sterilizing comedones in some patients.

References

  1. Leyden JJ. The acne challenge: management in an age of antibiotic resistance [online]. CME Certified Monograph. Medical Crossfire 2002; 3. Available from URL: http://www.medicalcrossfire.com/debate_archive/2002/Special_Editions/acne.pdf [Accessed 2003 Sep 4]

  2. Webster GF. Acne vulgaris. BMJ 2002; 325: 475–8

    Article  PubMed  Google Scholar 

  3. Whiteside JA, Voss JG. Incidence and lipolytic activity of Propionibacterium acnes (Corynebacterium acnes group I) and P. granulosum (C. acnes group II) in acne and in normal skin. J Invest Dermatol 1973; 60: 94–7

    Article  PubMed  CAS  Google Scholar 

  4. Marples RR, McGinley KJ, Mills OH. Microbiology of comedones in acne vulgaris. J Invest Dermatol 1973; 60: 80–3

    Article  PubMed  CAS  Google Scholar 

  5. Leyden JJ, McGinley KJ, Mills OH, et al. Propionibacterium levels in patients with and without acne vulgaris. J Invest Dermatol 1975; 65: 382–4

    Article  PubMed  CAS  Google Scholar 

  6. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998; 12: 12–26

    Article  PubMed  CAS  Google Scholar 

  7. Keicho N, Kudoh S, Yotsumoto H, et al. Antilymphocytic activity of erythromycin distinct from that of FK506 or cyclosporin A. J Antibiot (Tokyo) 1993; 46: 1406–13

    Article  CAS  Google Scholar 

  8. Viora M, de Luca A, D’Ambrosio A, et al. In vitro and in vivo immunomodulatory effects of anti-Pneumocystis carinii drugs. Antimicrob Agents Chemother 1996; 40: 1294–7

    PubMed  CAS  Google Scholar 

  9. Hand WL, Corwin RW, Steinberg TH, et al. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis 1984; 129: 933–7

    PubMed  CAS  Google Scholar 

  10. Murdoch MB, Peterson LR. Antimicrobial penetration into polymorphonuclear leucocytes and alveolar macrophages. Semin Respir Infect 1991; 6: 112–21

    PubMed  CAS  Google Scholar 

  11. Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459–64

    Article  PubMed  CAS  Google Scholar 

  12. Ferguson J. Recent trends in the prescribing of antibiotics. Prescriber 2001; 12: 59–62

    Google Scholar 

  13. Martin WJ, Gardner M, Washington JA. In vitro antimicrobial susceptibility of anaerobic bacteria isolated from clinical specimens. Antimicrob Agents Chemother 1972; 1: 148–58

    Article  PubMed  CAS  Google Scholar 

  14. Chow AW, Patten V, Guze LB. Comparative susceptibility of anaerobic bacteria to minocycline, doxycycline and tetracycline. Antimicrob Agents Chemother 1975; 7: 46–9

    Article  PubMed  CAS  Google Scholar 

  15. Guin JD, Huber DS, Gielerak PL. Antibiotic susceptibility of comedonal Propionibacterium acnes. Acta Derm Venereol 1979; 59: 552–4

    PubMed  CAS  Google Scholar 

  16. Crawford WW, Crawford IP, Stoughton RB, et al. Laboratory induction and clinical occurence of combined clindamycin and erythromycin resistance in Corynebacterium acnes. J Invest Dermatol 1979; 72: 187–90

    Article  PubMed  CAS  Google Scholar 

  17. Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. Med J Aust 1998; 169: 259–61

    PubMed  CAS  Google Scholar 

  18. Flühr JW, Gloor M, Dietz P, et al. In vitro activity of 6 antimicrobials against propionibacterial isolates from untreated acne papulopustulosa. Zentralbl Bakteriol 1999; 289: 53–61

    Article  PubMed  Google Scholar 

  19. Dréno B, Reynaud A, Moyse D, et al. Erythromycin resistance of cutaneous bacterial flora in acne. Eur J Dermatol 2001; 11: 549–53

    PubMed  Google Scholar 

  20. Tan HH, Goh CKL, Yeo MGC, et al. Antibiotic susceptibility of Propionibacterium acnes isolates from patients with acne vulgaris in a tertiary dermatological referral centre in Singapore. Ann Acad Med Singapore 2001; 30: 22–5

    PubMed  CAS  Google Scholar 

  21. Ross JI, Snelling AM, Carnegie E, et al. Antibiotic resistant acne: lessons from Europe. Br J Dermatol 2003; 148: 467–78

    Article  PubMed  CAS  Google Scholar 

  22. Leyden JJ. Historical perspective on the emergence of propionibacterial resistance: current views on how to combat the problem [oral presentation]. Australasian College of Dermatologists Annual Meeting; 1998 May; Melbourne

    Google Scholar 

  23. Coates P, Vyakrnam S, Eady EA, et al. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br J Dermatol 2002; 146: 840–8

    Article  PubMed  CAS  Google Scholar 

  24. Leyden JJ, McGinley KJ, Cavalieri S, et al. Propionibacterium acnes resistance to antibiotics in acne patients. J Am Acad Dermatol 1983; 8: 41–5

    Article  PubMed  CAS  Google Scholar 

  25. Leeming JP, Holland KT, Cunliffe WJ. The microbial ecology of inflamed acne vulgaris lesions. Br J Dermatol 1988; 118: 203–8

    Article  PubMed  CAS  Google Scholar 

  26. Eady EA, Cove JH, Holland KT, et al. Erythromycin resistant propionibacteria in antibiotic treated acne patients: association with therapeutic failure. Br J Dermatol 1989; 121: 51–7

    Article  PubMed  CAS  Google Scholar 

  27. Ross JI, Eady EA, Carnegie E, et al. Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J Antimicrob Chemother 2002; 49: 165–8

    Article  PubMed  CAS  Google Scholar 

  28. Ozolins M, Eady EA, Avery A, et al. A randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. NHS Health Technology Assessment Programme Monograph, 2003. In press (see URL http://www.ncchta.org/ProjectData/3_publication_listings_ALL.asp)

  29. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the USA, Japan and Australia. Br J Dermatol 2001; 144: 339–46

    Article  PubMed  CAS  Google Scholar 

  30. Frisk AR, Tunevall G. Clinical evaluation of minocycline. Antimicrob Agents Chemother 1968; 8: 335–9

    PubMed  CAS  Google Scholar 

  31. MacDonald H, Kelly RG, Allen ES, et al. Pharmacokinetic studies of minocycline in man. Clin Pharmacol Ther 1973; 14: 852–61

    PubMed  CAS  Google Scholar 

  32. Sjölin-Forsberg G, Hermansson J. Comparative bioavailability of tetracycline and lymecycline. Br J Clin Pharmacol 1984; 18: 529–33

    Article  PubMed  Google Scholar 

  33. Pascale D, Gordon J, Lamster I, et al. Concentration of doxycycline in human gingival fluid. J Clin Periodontol 1986; 13: 841–4

    Article  PubMed  CAS  Google Scholar 

  34. Gardner KJ, Eady EA, Cove JH, et al. Comparison of serum antibiotic levels in acne patients receiving the standard or a modified release formulation of minocycline hydrochloride. Clin Exp Dermatol 1997; 22: 72–6

    Article  PubMed  CAS  Google Scholar 

  35. Rashleigh PL, Rife E, Goltz RW. Tetracycline levels in skin surface film after oral administration of tetracycline to normal adults and to patients with acne vulgaris. J Invest Dermatol 1967; 49: 611–5

    PubMed  CAS  Google Scholar 

  36. Aubin F, Blanc D, Guinchard C, et al. Absence of minocycline in sebum? J Dermatol 1989; 16: 369–73

    PubMed  CAS  Google Scholar 

  37. Eady EA, Jones CE, Gardner KJ, et al. Tetracycline-resistant propionibacteria from acne patients are cross-resistant to doxycycline but sensitive to minocycline. Br J Dermatol 1993; 128: 556–60

    Article  PubMed  CAS  Google Scholar 

  38. British National Formulary (BNF). Tetracyclines [online]. BNF 2003 Sep; vol. 46, s. 5.1.3 Available from URL: http://www.BNF.org [Accessed 2003 Oct 30]

  39. Bearden DT, Danziger LH. Mechanism of action and resistance to the quinolones. Pharmacotherapy 2001; 21: 224S-32S

    Article  Google Scholar 

  40. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337–41

    Article  PubMed  CAS  Google Scholar 

  41. Guin JD, Lummis WL. Comedonal levels of free clindamycin following topical treatment with a 1% solution of clindamycin phosphate. J Am Acad Dermatol 1982; 7: 265–8

    Article  PubMed  CAS  Google Scholar 

  42. Gardner KJ, Cunliffe WJ, Eady EA, et al. Variation in comedonal antibiotic concentrations following application of topical tetracycline for acne vulgaris. Br J Dermatol 1994; 131: 649–54

    Article  PubMed  CAS  Google Scholar 

  43. Leyden J, Kaidbey K, Levy SF. The combination formulation of clindamycin 1% plus benzoyl peroxide 5% versus 3 different formulations of topical clindamycin alone in the reduction of Propionibacterium acnes. Am J Clin Dermatol 2001; 2: 263–6

    Article  PubMed  CAS  Google Scholar 

  44. Leyden J, Levy S. The development of resistance in Propionibacterium acnes. Cutis 2001; 67: 21–4

    PubMed  CAS  Google Scholar 

  45. Cunliffe WJ, Holland KT, Bojar RA, et al. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117–33

    Article  PubMed  CAS  Google Scholar 

  46. Eady EA, Bojar RA, Jones CE, et al. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin resistant propionibacteria. Br J Dermatol 1996; 134: 107–13

    Article  PubMed  CAS  Google Scholar 

  47. Bojar RA, Eady EA, Jones CE, et al. Inhibition of erythromycin-resistant propionibacteria on the skin of acne patients by topical erythromycin with and without zinc. Br J Dermatol 1994; 130: 329–36

    Article  PubMed  CAS  Google Scholar 

  48. Apraiz D, Quintanilla E. Estudio bacteriológico y resistencia bacteriana del Propionibacterium acnes en el acné vulgar. Rev Diag Biol 1988; 37: 63–6

    Google Scholar 

  49. Chalker DK, Shalita A, Smith JG, et al. A double-blind study of the effectiveness of a 3% erythromycin and 5% benzoyl peroxide formulation in the treatment of acne vulgaris. J Am Acad Dermatol 1983; 9: 933–6

    Article  PubMed  CAS  Google Scholar 

  50. Leyden JJ, Hicjman JG, Jarratt MT, et al. The efficacy and safety of a combination benzoyl peroxide /clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J Cutan Med Surg 2001; 5: 37–42

    PubMed  CAS  Google Scholar 

  51. Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne with a combination clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and vehicle gel: combined results of two double-blind investigations. J Am Acad Dermatol 1997; 37: 590–5

    Article  PubMed  CAS  Google Scholar 

  52. Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide and erythromycin alone and in combination against antibiotic-sensitive and resistant skin bacteria from acne patients. Br J Dermatol 1994; 131: 331–6

    Article  PubMed  CAS  Google Scholar 

  53. Burkhardt CN, Specht K, Neckers D. Synergistic activity of benzoyl peroxide and erythromycin. Skin Pharmacol Appl Skin Physiol 2000; 13: 292–6

    Google Scholar 

  54. Wyatt TD, Ferguson WP, Wilson TS, et al. Gentamicin resistant Staphylococcus aureus associated with the use of topical gentamicin. J Antimicrob Chemother 1977; 3: 213–7

    Article  PubMed  CAS  Google Scholar 

  55. Eady EA, Ross JI, Cove JH, et al. The effects of oral erythromycin therapy for acne on the development of resistance in cutaneous staphylococci and propionibacteria. In: Marks R, Plewig G, editors. Acne and related disorders. London: Dunitz, 1989: 265–70

    Google Scholar 

  56. Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 1995; 132: 204–8

    Article  PubMed  CAS  Google Scholar 

  57. King K, Jones DH, Daltrey DC, et al. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol 1982; 107: 583–90

    Article  PubMed  CAS  Google Scholar 

  58. Farmery MR, Jones CE, Eady EA, et al. In vitro activity of azelaic acid, benzoyl peroxide and zinc acetate against antibiotic-resistant propionibacteria from acne patients. J Dermatol Treat 1994; 5: 63–5

    Article  Google Scholar 

  59. Flühr JW, Bosch B, Gloor M, et al. In-vitro and in-vivo efficacy of zinc acetate against propionibacteria alone and in combination with erythromycin. Zentralbl Bakteriol 1999; 289: 445–56

    Article  PubMed  Google Scholar 

  60. McGinley KJ, Webster GF, Leyden JJ. Regional variation of cutaneous propionibacteria. Appl Environ Microbiol 1978; 35: 62–6

    PubMed  CAS  Google Scholar 

  61. Singer TR, Isenberg SJ, Apt L. Conjunctival anaerobic and aerobic bacterial flora in paediatric versus adult subjects. Br J Ophthalmol 1988; 72: 448–51

    Article  PubMed  CAS  Google Scholar 

  62. Gerstener GJ, Grunberger W, Boschitsch E, et al. Vaginal organisms in prepubertal children with and without vulvovaginitis: a vaginoscopic study. Arch Gynaecol 1982; 231: 247–52

    Article  Google Scholar 

  63. Sutter VL. Anaerobes as normal oral flora. Rev Infect Dis 1984; 6 Suppl. 1: S62–6

    Article  Google Scholar 

  64. Macfarlane GT, Cummings JH, Allison C. Protein degradation by human intestinal bacteria. J Gen Microbiol 1986; 132: 1647–56

    PubMed  CAS  Google Scholar 

  65. Neubert U, Plewig G, Ruhfus A. Treatment of gram-negative folliculitis with isotretinoin. Arch Dermatol Res 1986; 278: 307–13

    Article  PubMed  CAS  Google Scholar 

  66. Lotem M, Ingber A, Filhaber A, et al. Skin infection provoked by coagulase-negative Staphylococcus resembling gram-negative folliculitis. Cutis 1988; 42: 443–4

    PubMed  CAS  Google Scholar 

  67. Sturkenboom MC, Meier CR, Jick H, et al. Minocycline and lupuslike syndrome in acne patients. Arch Intern Med 1999; 159: 493–7

    Article  PubMed  CAS  Google Scholar 

  68. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline and doxycycline. Arch Dermatol 1997; 133: 1224–30

    Article  PubMed  CAS  Google Scholar 

  69. Lawrenson RA, Seaman HE, Sundstrom A, et al. Liver damage associated with minocycline use in acne: a systematic review of the published literature and pharmacovigilance data. Drug Saf 2000; 23: 333–49

    Article  PubMed  CAS  Google Scholar 

  70. Eady EA, Ingham E. Propionibacterium acnes: friend or foe? Rev Med Microbiol 1994; 5: 163–73

    Article  Google Scholar 

  71. Mills O, Thornsberry C, Cardin CW, et al. Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. Acta Dermatol Venereol 2002; 82: 260–5

    Article  CAS  Google Scholar 

  72. Eady EA, Holland KT, Cunliffe WJ. The use of antibiotics in acne therapy: oral or topical administration? J Antimicrob Chemother 1982; 10: 89–115

    Article  PubMed  CAS  Google Scholar 

  73. Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol 2003; 139: 467–71

    Article  PubMed  CAS  Google Scholar 

  74. Layton AM, Cunliffe WJ, Eady EA. Cutaneous infections are not a significant feature of patients treated with topical clindamycin. J Dermatol Treat 1989; 1: 75–7

    Article  Google Scholar 

  75. Masio CM, Gutierrez RF. Antifungal drug resistance to azoles and polyenes. Lancet Infect Dis 2002; 2: 550–63

    Article  Google Scholar 

  76. Eady EA, Ross JI, Cove JH, et al. Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes. J Antimicrob Chemother 1989; 23: 493–502

    Article  PubMed  CAS  Google Scholar 

  77. National Institute of Clinical Excellence (NICE). Referral practice: a guide to appropriate referral from general to specialist services (version under pilot) [online]. NICE 2000 May: 15–17. Available from URL: http://www.nice.org.uk/pdf/NICE_GP_Referral_cues_4.pdf [Accessed 2003 Oct 30]

    Google Scholar 

  78. Cunliffe WJ, van de Kerkhof PC, Caputo R, et al. Roaccutane treatment guidelines: results of an international survey. Dermatology 1997; 194: 351–7

    Article  PubMed  CAS  Google Scholar 

  79. Lucky AW, Biro FM, Simbartl LA, et al. Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study. J Paediatr 1997; 130: 30–9

    Article  CAS  Google Scholar 

  80. Burke BM, Cunliffe WJ. The assessment of acne: the Leeds technique. Br J Dermatol 1984; 111: 83–92

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We wish to thank colleagues in the Skin Research Centre at the University of Leeds who have helped to shape our ideas on the role of propionibacteria in acne. We also thank IMS Health for provision of the UK acne prescribing data. Anne Eady and Alison Layton have no existing conflicts of interest to disclose. Jonathan Cove receives grant funding from Dermik Laboratories Inc. (Aventis) and from Roche for studies related to the content of this article.

Author information

Authors and Affiliations

  1. Division of Microbiology, School of Biochemistry and Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK

    Anne E. Eady &  Jonathan H. Cove

  2. Department of Dermatology, Harrogate District Hospital, Harrogate, UK

    Alison M. Layton

Authors
  1. Anne E. Eady
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan H. Cove
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alison M. Layton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan H. Cove.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eady, A.E., Cove, J.H. & Layton, A.M. Is Antibiotic Resistance in Cutaneous Propionibacteria Clinically Relevant?. Am J Clin Dermatol 4, 813–831 (2003). https://doi.org/10.2165/00128071-200304120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200304120-00002

Keywords

Search

Navigation